SCHEMBL9901634

SCHEMBL9901634

Fc1ccc(Oc2ccc(CCOc3nc(Cl)ncc3F)cc2F)cc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.41
CASP6 P55212 1/20 0.41
ALDH1A1 P00352 2/20 0.39
GAA P10253 1/20 0.39
PIN1 Q13526 3/20 0.36
HTT P42858 1/20 0.35
PLA2G7 Q13093 2/20 0.33
GPR84 Q9NQS5 1/20 0.33
PPARG P37231 2/20 0.32
PPARA Q07869 1/20 0.32
HTR2A P28223 1/20 0.32
SLC6A4 P31645 1/20 0.32
KDM4E B2RXH2 2/20 0.32
MEN1 O00255 2/20 0.32
MAPT P10636 2/20 0.32
KMT2A Q03164 2/20 0.32
MAPK14 Q16539 1/20 0.31
ROCK2 O75116 1/20 0.31
ROCK1 Q13464 1/20 0.31
TRPA1 O75762 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15277244 0.87 MET (0.35) PPARGPPARAHTR2ASLC6A4ROCK2
SCHEMBL9901117 0.84 POLB (0.38) POLBCASP6ALDH1A1GAAPIN1
SCHEMBL9923434 0.81 SCN9A (0.39) ALDH1A1HTR2ASLC6A4MEN1KMT2A
SCHEMBL9901003 0.81 PLA2G7 (0.41) POLBCASP6ALDH1A1GAAPLA2G7
SCHEMBL9900548 0.79 MAOA (0.39) POLBCASP6ALDH1A1GAAPIN1
SCHEMBL9904872 0.78 TRPA1 (0.34) HTR2ASLC6A4TRPA1MET
SCHEMBL15262573 0.78 L3MBTL1 (0.46) POLBALDH1A1GAAMEN1MAPT
SCHEMBL9900937 0.76 PIN1 (0.49) POLBCASP6ALDH1A1GAAPIN1
SCHEMBL9900905 0.76 PIN1 (0.51) POLBCASP6PIN1PPARGFFAR1
SCHEMBL9901204 0.76 POLB (0.45) POLBCASP6ALDH1A1GAAPIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8859573-B2 Pyrimidinone and pyridinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 GLAXO GROUP LIMITED (GB) 2014-10-14 US disclosed
US-8859573-B2 Pyrimidinone and pyridinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 GLAXO GROUP LIMITED (GB) 2014-10-14 US disclosed
US-8859573-B2 Pyrimidinone and pyridinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 GLAXO GROUP LIMITED (GB) 2014-10-14 US disclosed
EP-2649050-A1 COMPOUNDS Glaxo Group Limited (GB) 2013-10-16 EP disclosed
US-20130252986-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-09-26 US disclosed
US-20130252986-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-09-26 US disclosed
US-20130252986-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-09-26 US disclosed
WO-2012075917-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2012-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252986-A1 COMPOUNDS LIPG, ENPP2, PLA2G1B POLB 2258/4885CASP6 1331/4885ALDH1A1 3180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.